Literature DB >> 30646022

Estimated Change in Prevalence of Hypertension in Nepal Following Application of the 2017 ACC/AHA Guideline.

Gulam Muhammed Al Kibria1, Krystal Swasey1, Angela Kc2, Mohammadhassan Mirbolouk3, Muhammad Nazmus Sakib4, Atia Sharmeen5, Mahmuda Jahan Chadni6, Kristen A Stafford1.   

Abstract

Importance: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults lowered the systolic and diastolic blood pressure thresholds for hypertension to 130 and 80 mm Hg, respectively. This represents a reduction of 10 mm Hg in both systolic and diastolic blood pressure levels used to define hypertension compared with previous guidelines, such as the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).
Objectives: To estimate the prevalence of hypertension among adults aged 18 years or older in Nepal per the 2017 ACC/AHA guideline and to determine the absolute difference in hypertension prevalence comparing the 2017 ACC/AHA and JNC 7 guidelines. Design, Setting, and Participants: The cross-sectional analysis used data from the population-based 2016 Nepal Demographic and Health Survey. Data were collected from June 2016 to January 2017 using a multistage stratified sampling procedure that was applied in urban and rural areas, using wards as the primary sampling units. Individuals aged 15 years or older from selected households were interviewed. The survey had an overall response rate of approximately 97%. Main Outcomes and Measures: The primary outcome was the prevalence of hypertension. Blood pressure was measured 3 times for each participant with 5-minute intervals between. Hypertension was present if blood pressure was greater than or equal to 130/80 mm Hg for the 2017 ACC/AHA guideline, and greater than or equal to 140/90 mm Hg for the JNC 7 guideline.
Results: Among 13 519 participants (median [interquartile range] age, 38 [26-53] years; 7821 [57.9%] female), 44.2% (95% CI, 43.4%-45.0%; n = 5977) had hypertension according to the 2017 ACC/AHA guideline compared with 21.2% (95% CI, 20.5%-21.9%; n = 2869) by the JNC 7 guideline. The new prevalence was associated with an absolute increase of 23.0% (95% CI, 22.3%-23.7%) from the JNC 7 guideline. When estimating the proportion of hypertension by background characteristics, the new 2017 ACC/AHA guideline definition increased the prevalence to 50% or greater for some categories, with the highest prevalence among those with a body mass index (calculated as weight in kilograms divided by height in meters squared) greater than or equal to 30 (71.6%; 95% CI, 67.7%-75.3%) and between 25 and 29.9 (62.1%; 95% CI, 60.1%-64.1%). Conclusions and Relevance: For adults in Nepal, the new 2017 ACC/AHA guideline reveals a greater estimated prevalence of hypertension compared with the JNC 7 guideline. Because of the public health significance of hypertension, higher prevalence rates confirm the importance of developing effective prevention and control methods in this country.

Entities:  

Mesh:

Year:  2018        PMID: 30646022      PMCID: PMC6324293          DOI: 10.1001/jamanetworkopen.2018.0606

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


Introduction

The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults lowered the threshold for the definition of hypertension. The 2017 ACC/AHA guideline describes the condition as a systolic blood pressure (SBP) greater than or equal to 130 mm Hg or a diastolic blood pressure (DBP) greater than or equal to 80 mm Hg.[1] Previous guidelines, such as the 1999 World Health Organization–International Society of Hypertension Guideline (1999 WHO-ISH)[2] and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), defined hypertension as an SBP greater than or equal to 140 mm Hg or a DBP greater than or equal to 90 mm Hg.[3] Application of this revised definition may reclassify a significant proportion of people as hypertensive who were previously categorized as prehypertensive, or people with high normal blood pressure. The benefit of this would be to potentially catch individuals earlier in disease progression and reduce cardiovascular morbidity and mortality.[1] This new evidence-based recommendation has prompted researchers to estimate an updated prevalence of hypertension; a growing body of literature has recognized the importance of the adjusted definition.[4,5,6] Implications of this new guideline highlight the importance of having revised estimates for all countries to aid public health resource planning and prevention strategies, as the prevalence of hypertension varies by region. The estimates that used the previous definition of 140/90 mm Hg found that prevalence of hypertension could vary according to age and sex, as well as education and other sociodemographic characteristics.[1,6] While prevalence is not the ideal measure by which to estimate risk factors for a clinical condition, it may be useful to identify subgroups who may benefit from public health interventions. A number of studies to date have estimated the adjusted prevalence of hypertension in some countries according to the new guideline.[5,6] Muntner et al[6] examined the effects of the new definition by assessing the hypertension prevalence in the United States and found an absolute increase of 14.7% among people aged 20 years or older. Additionally, Khera et al[5] estimated the relative increase of prevalence among adults aged 45 to 75 years in the United States and China and found an overall relative increase of 45.1% and 26.8% in these 2 countries, respectively. Estimating an updated prevalence for developing countries could be of particular interest because there is not only a lack of information available from these regions, but also an increasing burden of cardiovascular diseases.[7,8,9,10] Although prior studies have shown that hypertension and other cardiovascular diseases were the leading causes of global deaths and disability-adjusted life-years,[7,8,9] updated measures may more accurately demonstrate the burden of this illness. The 2016 Nepal Demographic and Health Survey (2016 NDHS) included blood pressure measurements among the variables collected from the study sample.[10] Nepal is a developing country in South Asia with an estimated land mass of 143 351 km2 and a population of about 29 million. This landlocked country is divided into 7 administrative provinces.[11] Most of the population is engaged in agriculture, and nearly 59% of people reside in urban regions.[10,11] Using the 1999 WHO-ISH guideline, among people aged 15 years or older, the 2016 NDHS estimated the hypertension prevalence as 23% and 17% among men and women, respectively.[10] The aim of this study was to estimate the prevalence of hypertension among adults (aged ≥18 years) in Nepal after applying the new 2017 ACC/AHA guideline. In addition, we compared this new 2017 ACC/AHA prevalence with the prevalence from the older JNC 7 guideline’s hypertension definition to determine the absolute differences in the prevalence of this condition according to stages and background characteristics.

Methods

Data Source

This study analyzed the cross-sectional survey data set of the 2016 NDHS. The survey was implemented from June 2016 to January 2017. New ERA, a private research organization in Nepal, conducted this survey. The main objective of this survey was to provide updated estimates of demographic and health indicators. The consulting services company ICF provided technical assistance to the survey as well as approval to use the data for secondary analyses. The Nepal Health Research Council and the ICF institutional review board approved the 2016 NDHS survey protocol. The head of household provided written informed consent before the interview.[10] We obtained the approval to use the data for the current study from ICF in January 2018. The institutional review board of the University of Maryland, Baltimore, exempted the study from oversight as it was not human subjects research.

Study Population and Survey Design

An updated version of the frame from the 2011 Population and Housing Census was used in the sampling frame. A 2-stage stratified sample was used in rural areas. The primary sampling units in rural areas were wards (n = 199). The households were selected from the primary sampling units in the second stage.[10] In urban regions, the sample was selected in 3 stages. The primary sampling unit was a ward (n = 184). Then, 1 enumeration area was randomly selected from each ward, and households were selected from enumeration area. Each cluster (enumeration area or ward) expected to have 30 households, which would yield a total of 11 490 households. All women and men aged 15 years or older were eligible for blood pressure measurements in half of the households.[10] These households were then visited and interviewed. The overall response rate was approximately 97%. A total unweighted sample of 5571 men and 7861 women aged 18 years or older was interviewed. Details of this population-based survey, including survey design, methods, questionnaires, and sample size determination, have been described elsewhere.[10]

Measurements

The blood pressure of the survey participants was measured with UA-767F/FAC blood pressure monitors (A&D Medical). Blood pressure was measured 3 times for each individual with an interval of 5 minutes between the measurements. The mean of the last 2 measurements was used to define and categorize the final pressure level.[10]

Definition of Hypertension

According to the JNC 7 guideline, individuals who have an SBP greater than or equal to 140 mm Hg or a DBP greater than or equal to 90 mm Hg or take any prescribed drugs to control blood pressure were categorized as hypertensive. According to the 2017 ACC/AHA guideline, individuals who have an SBP greater than or equal to 130 mm Hg or a DBP greater than or equal to 80 mm Hg or take any prescribed drugs to control blood pressure were categorized as hypertensive. The category of prehypertension was changed to elevated blood pressure in the 2017 ACC/AHA guideline.[1] eTable 1 in the Supplement shows definitions, categories, and ascertainment methods of all variables used to estimate the prevalence in this study.

Statistical Analysis

All variables were first investigated in univariate analyses before estimating the prevalence of hypertension. The normality of the continuous variables was assessed, and variables with a skewed distribution were reported with medians and interquartile ranges (IQRs). The prevalence was estimated for both guidelines; we then estimated the absolute differences between the prevalence of hypertension according to the 2 guidelines. All prevalences and differences were reported with 95% confidence intervals according to blood pressure stages and guidelines. The background characteristics to report the estimates were adapted from the WHO-recommended standard reporting format.[12] In addition, we reported the prevalence for each of the background characteristics of the study participants. We considered the hierarchical structure of the data set to estimate the prevalence. Stata statistical software version 14.0 (StataCorp) was used to analyze data in this study.[13] We conducted weighted analysis to adjust for the clustered sampling design of the survey.[10]

Results

A total of 13 519 weighted participants were included in this analysis. The median (IQR) age of the respondents was 38 (26-53) years, and 57.9% (n = 7821) were women (Table 1). Overall, the median (IQR) SBP and DBP were 113 (104-125) and 77 (70-85) mm Hg, respectively. The JNC 7 described 2869 participants (21.2%) as hypertensive, while the 2017 ACC/AHA categorized 5977 people (44.2%) as hypertensive. Most participants (81.4%) reported having their blood pressure measured previously at least once. Of survey participants categorized as hypertensive per the JNC 7 guideline, 40.4% (n = 1160) knew their hypertension status; this proportion was 23.6% (n = 1408) among those classified as hypertensive per the 2017 ACC/AHA guideline. Only 20.4% of those who would have been considered hypertensive per the JNC 7 guideline were taking antihypertensive medications, while this proportion was 9.8% using the 2017 ACC/AHA guideline (n = 584). Of the people who had hypertension according to the JNC 7 and 2017 ACC/AHA guidelines, about 9.7% (n = 280) and 7.2% (n = 431) had a controlled blood pressure level, respectively. The median (IQR) body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) of those classified as hypertensive per the JNC 7 guideline (23.1 [20.4-26.3]) was slightly higher compared with those classified as hypertensive per the 2017 ACC/AHA guideline (22.6 [20.2-25.7]) and all respondents (21.4 [19.3-24.2]). Of all survey respondents, 41.0% (n = 5546) had no formal education, regardless of hypertension status. The proportion of urban residents was more than 60% among the overall population as well as among those classified as hypertensive under both guidelines. Unweighted characteristics of the study population are available in eTable 2 in the Supplement.
Table 1.

Background Characteristics of the Weighted Survey Participants

CharacteristicsAll Participants (N = 13 519), No. (%)Participants With Hypertension per JNC 7 (n = 2869), No. (%)Participants With Hypertension per 2017 ACC/AHA (n = 5977), No. (%)
SBP, median (IQR), mm Hg113 (104-125)141 (129-154)126 (118-140)
DBP, median (IQR), mm Hg77 (70-85)93 (89-99)86 (82-92)
Ever measured blood pressure10 997 (81.4)2480 (86.5)5038 (84.3)
Know hypertension status1678 (12.4)1160 (40.4)1408 (23.6)
Taking antihypertensive medication584 (4.3)584 (20.4)584 (9.8)
Controlled blood pressure levelNA280 (9.7)431 (7.2)
Age, y
Median (IQR)38.0 (26.0-53.0)51.0 (39.0-63.0)44.0 (33.0-57.0)
18-294383 (32.4)266 (9.3)1079 (18.1)
30-495024 (37.2)1089 (38.0)2479 (41.5)
50-693209 (23.7)1111 (38.7)1865 (31.2)
≥70903 (6.7)403 (14.0)553 (9.3)
Sex
Male5697 (42.1)1453 (50.6)2897 (48.5)
Female7821 (57.9)1416 (49.4)3080 (51.5)
BMIa
Median (IQR)21.4 (19.3-24.2)23.1 (20.4-26.3)22.6 (20.2-25.7)
<18.52240 (16.8)311 (11.1)682 (11.6)
18.5-24.98242 (61.7)1473 (52.5)3359 (57.1)
25-29.92324 (17.4)785 (28.0)1444 (24.6)
≥30549 (4.1)236 (8.4)393 (6.7)
Education
No formal education5546 (41.0)1371 (47.8)2631 (44.0)
Primary2324 (17.2)526 (18.3)1073 (18.0)
Secondary3695 (27.3)659 (23.0)1521 (25.5)
College or above1951 (14.4)311 (10.8)749 (12.5)
Household wealth status
Poorest2408 (17.8)456 (15.9)1053 (17.6)
Poorer2617 (19.4)558 (19.5)1175 (19.7)
Middle2699 (20.0)483 (16.8)1090 (18.2)
Richer2945 (21.8)557 (19.4)1206 (20.2)
Richest2850 (21.1)814 (28.4)1451 (24.3)
Place of residence
Urban8274 (61.2)1852 (64.5)3740 (62.6)
Rural5244 (38.8)1017 (35.5)2237 (37.4)
Ecological zone
Mountain860 (6.4)157 (5.5)354 (5.9)
Hill5964 (44.1)1449 (50.5)2906 (48.6)
Terai6695 (49.5)1263 (44.0)2716 (45.4)
Province
12392 (17.7)488 (17.0)1017 (17.0)
22770 (20.5)450 (15.7)977 (16.4)
32976 (22.0)740 (25.8)1446 (24.2)
41392 (10.3)400 (13.9)772 (12.9)
52197 (16.3)515 (18.0)1092 (18.3)
6677 (5.0)109 (3.8)265 (4.4)
71113 (8.2)166 (5.8)406 (6.8)

Abbreviations: ACC/AHA, 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NA, not applicable; SBP, systolic blood pressure.

Calculated as weight in kilograms divided by height in meters squared.

Abbreviations: ACC/AHA, 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NA, not applicable; SBP, systolic blood pressure. Calculated as weight in kilograms divided by height in meters squared. Table 2 summarizes the prevalence (with 95% confidence interval) of hypertension among men and women according to the 2 guidelines, along with the absolute difference in prevalence comparing the previous guidelines with the new guideline. The crude prevalence of hypertension was 21.2% (95% CI, 20.5%-21.9%) according to the JNC 7 guideline, compared with 44.2% (95% CI, 43.4%-45.0%) by the 2017 ACC/AHA guideline. More than half of the male respondents had hypertension according to the new classification (50.8% [95% CI, 49.5%-52.2%]), compared with 39.4% (95% CI, 38.3%-40.5%) of the female respondents. The prevalence for hypertension according to JNC 7 was 25.5% (95% CI, 24.4%-26.6%) among men and 18.1% (95% CI, 17.3%-19.0%) among women. Under the new guideline, the overall prevalence of hypertension was 23.0% (95% CI, 22.3%-23.7%) higher because of an equal reduction in the prevalence of prehypertension. Male respondents had a higher absolute increase in prevalence than their female counterparts (25.3% [95% CI, 24.2%-26.5%] and 21.3% [95% CI, 20.4%-22.2%], respectively). A similar percentage increase was observed for stage 1 and stage 2 hypertension for both sexes. The overall absolute increases for the prevalence of stage 1 and stage 2 hypertension were 10.6% (95% CI, 8.4%-12.8%) and 12.4% (95% CI, 11.8%-12.9%), respectively.
Table 2.

Weighted Prevalence and Absolute Changes in Prevalence According to JNC 7 and 2017 ACC/AHA Guideline

Blood PressurePrevalence per JNC 7, % (95% CI)Prevalence per 2017 ACC/AHA, % (95% CI)Absolute Difference, % (95% CI)
Men
Normal43.8 (42.5-45.1)43.8 (42.5-45.1)0
Prehypertension or elevated blood pressure30.7 (29.5-31.9)5.4 (4.8-6.0)−25.3 (−24.2 to −26.5)
Stage 1 hypertension17.3 (16.4-18.4)27.8 (26.7-29.0)10.5 (7.2-13.9)
Stage 2 hypertension8.1 (7.5-8.9)23.0 (21.9-24.1)14.9 (13.9-15.8)
Hypertension (stage 1 plus stage 2)25.5 (24.4-26.6)50.8 (49.5-52.2)25.3 (24.2-26.5)
Women
Normal57.7 (56.6-58.8)57.7 (56.6-58.8)0
Prehypertension or elevated blood pressure24.1 (23.2-25.1)2.9 (2.5-3.3)−21.3 (−20.4 to −22.2)
Stage 1 hypertension12.6 (11.9-13.4)23.4 (22.4-24.3)10.8 (7.7-13.6)
Stage 2 hypertension5.5 (5.0-6.0)16.0 (15.3-16.9)10.5 (9.9-11.2)
Hypertension (stage 1 plus stage 2)18.1 (17.3-19.0)39.4 (38.3-40.5)21.3 (20.4-22.2)
Overall
Normal51.9 (51.0-52.7)51.9 (51.0-52.7)0
Prehypertension or elevated blood pressure26.9 (26.2-27.7)3.9 (3.6-4.3)−23.0 (−22.3 to −23.7)
Stage 1 hypertension14.6 (14.0-15.2)25.2 (24.5-26.0)10.6 (8.4-12.8)
Stage 2 hypertension6.6 (6.2-7.0)19.0 (18.3-19.6)12.4 (11.8-12.9)
Hypertension (stage 1 plus stage 2)21.2 (20.5-21.9)44.2 (43.4-45.0)23.0 (22.3-23.7)

Abbreviations: ACC/AHA, 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Abbreviations: ACC/AHA, 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Among categories of individuals with hypertension according to the 2017 ACC/AHA guideline (Table 3), the highest rate was observed among people with a BMI of 30 or greater (71.6% [95% CI, 67.7%-75.3%]), followed by those with a BMI of 25 to 29.9 (62.1% [95% CI, 60.1%-64.1%]). Among different age groups, prevalence was highest among individuals aged 70 years or older (61.3% [95% CI, 58.1%-64.4%]), those aged 50 to 69 years (58.1% [95% CI, 56.4%-59.8%]), and those aged 30 to 49 years (49.3% [95% CI, 47.9%-50.7%]). Individuals in the richest household wealth quintile had higher rates (50.9% [95% CI, 49.1%-52.8%]), as did those living in a hill area (48.7% [95% CI, 47.5%-50.0%]), Province 4 (55.5% [95% CI, 52.8%-58.1%]), Province 5 (49.7% [95% CI, 47.6%-51.8%]), and Province 3 (48.6% [95% CI, 46.8%-50.4%]). None of the subgroups had more than 50% prevalence according to the JNC 7 guideline, with the highest prevalence among people aged 70 years or older (44.6% [95% CI, 41.4%-47.9%]) and those with a BMI of 30 or greater (43.0% [95% CI, 38.9%-47.2%]). Among those who were not hypertensive per the JNC 7 guideline, the new 2017 ACC/AHA guideline was associated with more than a 20% increase in newly identified hypertensive people in most of the categories.
Table 3.

Weighted Prevalence of Hypertension in Both Sexes According to Selected Demographic Characteristics

Demographic CharacteristicsPrevalence of Hypertension per JNC 7, % (95% CI)Prevalence of Hypertension per 2017 ACC/AHA, % (95% CI)Difference, % (95% CI)
Age, y
18-296.1 (5.4-6.8)24.6 (23.4-25.9)18.5 (17.4-19.7)
30-4921.7 (20.6-22.8)49.3 (47.9-50.7)27.6 (26.4-28.9)
50-6934.6 (33.0-36.3)58.1 (56.4-59.8)23.5 (22.1-25.0)
≥7044.6 (41.4-47.9)61.3 (58.1-64.4)16.7 (14.4-19.2)
BMIa
<18.513.9 (12.5-15.4)30.4 (28.6-32.4)16.5 (15.1-18.2)
18.5-24.917.9 (17.1-18.7)40.8 (39.7-41.8)22.9 (22.0-23.8)
25-29.933.7 (31.9-35.7)62.1 (60.1-64.1)28.4 (26.5-30.2)
≥3043.0 (38.9-47.2)71.6 (67.7-75.3)28.6 (25.0-32.6)
Education
No formal education24.7 (23.6-25.9)47.4 (46.1-48.7)22.7 (21.6-23.8)
Primary22.6 (21.0-24.4)46.2 (44.2-48.2)23.6 (21.9-25.3)
Secondary17.8 (16.6-19.1)41.2 (39.6-42.8)23.4 (22.0-24.7)
College or above15.9 (14.4-17.6)38.4 (36.2-40.6)22.5 (20.6-24.3)
Household wealth status
Poorest18.9 (17.4-20.6)43.7 (41.8-45.7)24.8 (23.1-26.6)
Poorer21.4 (19.8-23.0)44.9 (43.0-46.8)23.5 (21.9-25.2)
Middle17.9 (16.5-19.4)40.4 (38.6-42.3)22.5 (21.0-24.1)
Richer18.9 (17.5-20.4)41.0 (39.2-42.8)22.1 (20.6-23.6)
Richest28.5 (26.9-30.2)50.9 (49.1-52.8)22.4 (20.9-23.9)
Place of residence
Urban22.4 (21.5-23.3)45.2 (44.1-46.3)22.8 (21.9-23.7)
Rural19.4 (18.4-20.5)42.7 (41.3-44.0)23.3 (22.1-24.4)
Ecological zone
Mountain18.3 (15.8-21.0)41.2 (38.0-44.5)22.9 (20.2-25.9)
Hill24.3 (23.2-25.4)48.7 (47.5-50.0)24.4 (23.4-25.5)
Terai18.9 (17.9-19.8)40.6 (39.4-40.7)21.7 (20.7-22.7)
Province
120.4 (18.8-22.1)42.5 (40.6-44.5)22.1 (20.5-23.8)
216.2 (14.9-17.7)35.3 (33.5-37.1)19.1 (17.6-20.5)
324.9 (23.3-26.4)48.6 (46.8-50.4)23.7 (22.2-25.3)
428.8 (26.4-31.2)55.5 (52.8-58.1)26.7 (24.4-29.1)
523.4 (21.7-23.3)49.7 (47.6-51.8)26.3 (24.4-28.1)
616.2 (13.6-19.2)39.2 (35.6-42.9)23.0 (20.0-26.3)
714.9 (12.9-17.1)36.5 (33.7-39.4)21.6 (19.3-24.1)

Abbreviations: ACC/AHA, 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; BMI, body mass index; JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Calculated as weight in kilograms divided by height in meters squared.

Abbreviations: ACC/AHA, 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; BMI, body mass index; JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Calculated as weight in kilograms divided by height in meters squared.

Discussion

We investigated the change in estimated prevalence of hypertension in Nepal according to the lower blood pressure threshold recommended in the 2017 ACC/AHA guideline. Under the new guideline, 44.2% of adults in Nepal are now considered to have hypertension. In addition, regardless of background characteristics of the survey participants, these findings reclassified more than one-fifth of adults as hypertensive who were categorized as prehypertensive according to the JNC 7 guideline. The 2017 ACC/AHA guideline recommended a lower blood pressure threshold for the diagnosis of hypertension based on medical evidence indicating that even a small increase in blood pressure increases risks of morbidity and mortality.[1] Application of the new guideline should have a significant impact on hypertension prevention and management in countries like Nepal, where only one-fifth of the adult population who had hypertension according to previous guidelines (ie, the JNC 7 or 1999 WHO-ISH) were taking blood pressure–lowering drugs. In addition to our study, other studies that investigated the awareness and control of blood pressure among adults in Nepal found an overall lower level of control and awareness of hypertension in this country.[14,15] Furthermore, like many other developing countries, Nepal is facing a double burden of infectious and noncommunicable diseases that warrants national awareness and control programs.[16,17] Despite the similar absolute difference for prevalence of hypertension regardless of background characteristics, the 2017 ACC/AHA prevalence was higher depending on some background characteristics, such as age, BMI, and household wealth status; the same groups also had higher prevalence using the JNC 7 threshold. The determinants of hypertension are beyond the scope of this discussion; however, studies that investigated risk factors for hypertension in Nepal found a higher likelihood of hypertension among individuals who were older, had a higher BMI, and belonged to the highest quintile of household wealth.[18,19,20,21] These high-risk groups require more awareness and control of hypertension to minimize complications or negative consequences associated with hypertension.[1] The 2017 ACC/AHA guideline recommends treating stage 1 hypertension with lifestyle measures plus antihypertensive drugs for secondary prevention of clinical cardiovascular disease or for primary prevention of cardiovascular disease if the estimated 10-year risk of atherosclerotic cardiovascular disease is 10% or higher. Additionally, persons with stage 2 hypertension and an estimated 10-year risk of atherosclerotic cardiovascular disease greater than 10% are recommended to take antihypertensive drugs along with lifestyle measures. Patients with stage 1 hypertension who have a 10-year risk of atherosclerotic cardiovascular disease greater than 10% or elevated blood pressure would require lifestyle modification.[1] Our findings are also essential in the context that at least half of the adults in Nepal (those with either hypertension or elevated blood pressure) should follow active lifestyles and healthy dietary habits.[1] Public health programs should encourage active lifestyles and healthy diets among all people in this country, not just those with hypertension. We were unable to estimate the proportion of patients who could require antihypertensive medication because of limitations of the NDHS 2016 data set. This estimation is required to fully understand the burden of hypertension in Nepal. Of the few studies of which we are aware that examined the prevalence of hypertension according to the latest guideline, only Muntner et al[6] worked with a similar age group (ie, ≥20 years). They also found a similar absolute change in prevalence of hypertension after applying the new 2017 ACC/AHA guideline. This finding is important not only because Nepal and the United States are socioeconomically or demographically different, but also because each population had a substantial difference (10.4%) in the prevalence of hypertension according to the JNC 7 guideline for this age group.[6,10] Using the JNC 7 guideline, hypertension prevalence was 21.2% in Nepal and 31.6% in the United States. However, the 2017 ACC/AHA classified 44.2% and 45.6% of people as hypertensive in Nepal and the United States, respectively; the new estimates are very close to each other (1.4%).[6] Given the similar prevalence of hypertension in many other countries according to the JNC 7 guideline’s hypertension definition,[22,23] the prevalence of hypertension in other countries could be similar according to the 2017 ACC/AHA guideline’s thresholds. However, it is necessary to estimate both the prevalence of hypertension and the proportion requiring pharmacologic treatment for hypertension according to the 2017 ACC/AHA guideline in other countries to estimate the overall global burden of hypertension. In addition, evaluating the degree of awareness and control of blood pressure levels in Nepal and other countries according to the 2017 ACC/AHA guideline may be helpful in understanding the future research requirements needed to overcome this massive public health challenge. The strengths of this study include generalizability of the findings for Nepal, as this survey covered both urban and rural areas of all provinces in this country,[10] and also the use of appropriate statistical methods to estimate the weighted prevalence of hypertension from the study sample.

Limitations

The limitations of the current study also warrant discussion. The survey data set was cross-sectional, and blood pressure of the participants was measured 3 times in a single day. Both guidelines recommend longitudinal measurement of blood pressure levels to diagnose hypertension. Furthermore, this survey used an automated device, while both guidelines recommend recording blood pressure with a sphygmomanometer.[1,6,10] Although the survey staff were highly trained, their efficacy or skill level may cause some misclassification.[6,10,24]

Conclusions

The results of our study indicate that a significant proportion of the adults in Nepal may have hypertension according to the latest guideline. Considering the morbidity and mortality associated with hypertension, this condition is a major public health challenge for Nepal and other countries with similar sociodemographic characteristics. Our results signify the importance of implementing more awareness programs to control hypertension as well as minimizing complications associated with hypertension. In addition, similar research in other countries could be helpful to estimate country-specific burdens of hypertension.
  20 in total

1.  Double burden of noncommunicable and infectious diseases in developing countries.

Authors:  I C Bygbjerg
Journal:  Science       Date:  2012-09-21       Impact factor: 47.728

2.  Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.

Authors:  Paul Muntner; Robert M Carey; Samuel Gidding; Daniel W Jones; Sandra J Taler; Jackson T Wright; Paul K Whelton
Journal:  Circulation       Date:  2017-11-13       Impact factor: 29.690

3.  Awareness, treatment and control of hypertension in Nepal: findings from the Dhulikhel Heart Study.

Authors:  Biraj M Karmacharya; Rajendra P Koju; James P LoGerfo; Kwun Chuen Gary Chan; Ali H Mokdad; Archana Shrestha; Nona Sotoodehnia; Annette L Fitzpatrick
Journal:  Heart Asia       Date:  2017-01-04

4.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

Review 5.  Burgeoning burden of non-communicable diseases in Nepal: a scoping review.

Authors:  Shiva Raj Mishra; Dinesh Neupane; Parash Mani Bhandari; Vishnu Khanal; Per Kallestrup
Journal:  Global Health       Date:  2015-07-16       Impact factor: 4.185

6.  Barriers to Treatment and Control of Hypertension among Hypertensive Participants: A Community-Based Cross-sectional Mixed Method Study in Municipalities of Kathmandu, Nepal.

Authors:  Surya Devkota; Raja Ram Dhungana; Achyut Raj Pandey; Bihungum Bista; Savyata Panthi; Kartikesh Kumar Thakur; Ratna Mani Gajurel
Journal:  Front Cardiovasc Med       Date:  2016-08-02

Review 7.  Prevalence of hypertension in member countries of South Asian Association for Regional Cooperation (SAARC): systematic review and meta-analysis.

Authors:  Dinesh Neupane; Craig S McLachlan; Rajan Sharma; Bishal Gyawali; Vishnu Khanal; Shiva Raj Mishra; Bo Christensen; Per Kallestrup
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

8.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors:  Mohammad H Forouzanfar; Lily Alexander; H Ross Anderson; Victoria F Bachman; Stan Biryukov; Michael Brauer; Richard Burnett; Daniel Casey; Matthew M Coates; Aaron Cohen; Kristen Delwiche; Kara Estep; Joseph J Frostad; K C Astha; Hmwe H Kyu; Maziar Moradi-Lakeh; Marie Ng; Erica Leigh Slepak; Bernadette A Thomas; Joseph Wagner; Gunn Marit Aasvang; Cristiana Abbafati; Ayse Abbasoglu Ozgoren; Foad Abd-Allah; Semaw F Abera; Victor Aboyans; Biju Abraham; Jerry Puthenpurakal Abraham; Ibrahim Abubakar; Niveen M E Abu-Rmeileh; Tania C Aburto; Tom Achoki; Ademola Adelekan; Koranteng Adofo; Arsène K Adou; José C Adsuar; Ashkan Afshin; Emilie E Agardh; Mazin J Al Khabouri; Faris H Al Lami; Sayed Saidul Alam; Deena Alasfoor; Mohammed I Albittar; Miguel A Alegretti; Alicia V Aleman; Zewdie A Alemu; Rafael Alfonso-Cristancho; Samia Alhabib; Raghib Ali; Mohammed K Ali; François Alla; Peter Allebeck; Peter J Allen; Ubai Alsharif; Elena Alvarez; Nelson Alvis-Guzman; Adansi A Amankwaa; Azmeraw T Amare; Emmanuel A Ameh; Omid Ameli; Heresh Amini; Walid Ammar; Benjamin O Anderson; Carl Abelardo T Antonio; Palwasha Anwari; Solveig Argeseanu Cunningham; Johan Arnlöv; Valentina S Arsic Arsenijevic; Al Artaman; Rana J Asghar; Reza Assadi; Lydia S Atkins; Charles Atkinson; Marco A Avila; Baffour Awuah; Alaa Badawi; Maria C Bahit; Talal Bakfalouni; Kalpana Balakrishnan; Shivanthi Balalla; Ravi Kumar Balu; Amitava Banerjee; Ryan M Barber; Suzanne L Barker-Collo; Simon Barquera; Lars Barregard; Lope H Barrero; Tonatiuh Barrientos-Gutierrez; Ana C Basto-Abreu; Arindam Basu; Sanjay Basu; Mohammed O Basulaiman; Carolina Batis Ruvalcaba; Justin Beardsley; Neeraj Bedi; Tolesa Bekele; Michelle L Bell; Corina Benjet; Derrick A Bennett; Habib Benzian; Eduardo Bernabé; Tariku J Beyene; Neeraj Bhala; Ashish Bhalla; Zulfiqar A Bhutta; Boris Bikbov; Aref A Bin Abdulhak; Jed D Blore; Fiona M Blyth; Megan A Bohensky; Berrak Bora Başara; Guilherme Borges; Natan M Bornstein; Dipan Bose; Soufiane Boufous; Rupert R Bourne; Michael Brainin; Alexandra Brazinova; Nicholas J Breitborde; Hermann Brenner; Adam D M Briggs; David M Broday; Peter M Brooks; Nigel G Bruce; Traolach S Brugha; Bert Brunekreef; Rachelle Buchbinder; Linh N Bui; Gene Bukhman; Andrew G Bulloch; Michael Burch; Peter G J Burney; Ismael R Campos-Nonato; Julio C Campuzano; Alejandra J Cantoral; Jack Caravanos; Rosario Cárdenas; Elisabeth Cardis; David O Carpenter; Valeria Caso; Carlos A Castañeda-Orjuela; Ruben E Castro; Ferrán Catalá-López; Fiorella Cavalleri; Alanur Çavlin; Vineet K Chadha; Jung-Chen Chang; Fiona J Charlson; Honglei Chen; Wanqing Chen; Zhengming Chen; Peggy P Chiang; Odgerel Chimed-Ochir; Rajiv Chowdhury; Costas A Christophi; Ting-Wu Chuang; Sumeet S Chugh; Massimo Cirillo; Thomas K D Claßen; Valentina Colistro; Mercedes Colomar; Samantha M Colquhoun; Alejandra G Contreras; Cyrus Cooper; Kimberly Cooperrider; Leslie T Cooper; Josef Coresh; Karen J Courville; Michael H Criqui; Lucia Cuevas-Nasu; James Damsere-Derry; Hadi Danawi; Lalit Dandona; Rakhi Dandona; Paul I Dargan; Adrian Davis; Dragos V Davitoiu; Anand Dayama; E Filipa de Castro; Vanessa De la Cruz-Góngora; Diego De Leo; Graça de Lima; Louisa Degenhardt; Borja del Pozo-Cruz; Robert P Dellavalle; Kebede Deribe; Sarah Derrett; Don C Des Jarlais; Muluken Dessalegn; Gabrielle A deVeber; Karen M Devries; Samath D Dharmaratne; Mukesh K Dherani; Daniel Dicker; Eric L Ding; Klara Dokova; E Ray Dorsey; Tim R Driscoll; Leilei Duan; Adnan M Durrani; Beth E Ebel; Richard G Ellenbogen; Yousef M Elshrek; Matthias Endres; Sergey P Ermakov; Holly E Erskine; Babak Eshrati; Alireza Esteghamati; Saman Fahimi; Emerito Jose A Faraon; Farshad Farzadfar; Derek F J Fay; Valery L Feigin; Andrea B Feigl; Seyed-Mohammad Fereshtehnejad; Alize J Ferrari; Cleusa P Ferri; Abraham D Flaxman; Thomas D Fleming; Nataliya Foigt; Kyle J Foreman; Urbano Fra Paleo; Richard C Franklin; Belinda Gabbe; Lynne Gaffikin; Emmanuela Gakidou; Amiran Gamkrelidze; Fortuné G Gankpé; Ron T Gansevoort; Francisco A García-Guerra; Evariste Gasana; Johanna M Geleijnse; Bradford D Gessner; Pete Gething; Katherine B Gibney; Richard F Gillum; Ibrahim A M Ginawi; Maurice Giroud; Giorgia Giussani; Shifalika Goenka; Ketevan Goginashvili; Hector Gomez Dantes; Philimon Gona; Teresita Gonzalez de Cosio; Dinorah González-Castell; Carolyn C Gotay; Atsushi Goto; Hebe N Gouda; Richard L Guerrant; Harish C Gugnani; Francis Guillemin; David Gunnell; Rahul Gupta; Rajeev Gupta; Reyna A Gutiérrez; Nima Hafezi-Nejad; Holly Hagan; Maria Hagstromer; Yara A Halasa; Randah R Hamadeh; Mouhanad Hammami; Graeme J Hankey; Yuantao Hao; Hilda L Harb; Tilahun Nigatu Haregu; Josep Maria Haro; Rasmus Havmoeller; Simon I Hay; Mohammad T Hedayati; Ileana B Heredia-Pi; Lucia Hernandez; Kyle R Heuton; Pouria Heydarpour; Martha Hijar; Hans W Hoek; Howard J Hoffman; John C Hornberger; H Dean Hosgood; Damian G Hoy; Mohamed Hsairi; Guoqing Hu; Howard Hu; Cheng Huang; John J Huang; Bryan J Hubbell; Laetitia Huiart; Abdullatif Husseini; Marissa L Iannarone; Kim M Iburg; Bulat T Idrisov; Nayu Ikeda; Kaire Innos; Manami Inoue; Farhad Islami; Samaya Ismayilova; Kathryn H Jacobsen; Henrica A Jansen; Deborah L Jarvis; Simerjot K Jassal; Alejandra Jauregui; Sudha Jayaraman; Panniyammakal Jeemon; Paul N Jensen; Vivekanand Jha; Fan Jiang; Guohong Jiang; Ying Jiang; Jost B Jonas; Knud Juel; Haidong Kan; Sidibe S Kany Roseline; Nadim E Karam; André Karch; Corine K Karema; Ganesan Karthikeyan; Anil Kaul; Norito Kawakami; Dhruv S Kazi; Andrew H Kemp; Andre P Kengne; Andre Keren; Yousef S Khader; Shams Eldin Ali Hassan Khalifa; Ejaz A Khan; Young-Ho Khang; Shahab Khatibzadeh; Irma Khonelidze; Christian Kieling; Daniel Kim; Sungroul Kim; Yunjin Kim; Ruth W Kimokoti; Yohannes Kinfu; Jonas M Kinge; Brett M Kissela; Miia Kivipelto; Luke D Knibbs; Ann Kristin Knudsen; Yoshihiro Kokubo; M Rifat Kose; Soewarta Kosen; Alexander Kraemer; Michael Kravchenko; Sanjay Krishnaswami; Hans Kromhout; Tiffany Ku; Barthelemy Kuate Defo; Burcu Kucuk Bicer; Ernst J Kuipers; Chanda Kulkarni; Veena S Kulkarni; G Anil Kumar; Gene F Kwan; Taavi Lai; Arjun Lakshmana Balaji; Ratilal Lalloo; Tea Lallukka; Hilton Lam; Qing Lan; Van C Lansingh; Heidi J Larson; Anders Larsson; Dennis O Laryea; Pablo M Lavados; Alicia E Lawrynowicz; Janet L Leasher; Jong-Tae Lee; James Leigh; Ricky Leung; Miriam Levi; Yichong Li; Yongmei Li; Juan Liang; Xiaofeng Liang; Stephen S Lim; M Patrice Lindsay; Steven E Lipshultz; Shiwei Liu; Yang Liu; Belinda K Lloyd; Giancarlo Logroscino; Stephanie J London; Nancy Lopez; Joannie Lortet-Tieulent; Paulo A Lotufo; Rafael Lozano; Raimundas Lunevicius; Jixiang Ma; Stefan Ma; Vasco M P Machado; Michael F MacIntyre; Carlos Magis-Rodriguez; Abbas A Mahdi; Marek Majdan; Reza Malekzadeh; Srikanth Mangalam; Christopher C Mapoma; Marape Marape; Wagner Marcenes; David J Margolis; Christopher Margono; Guy B Marks; Randall V Martin; Melvin B Marzan; Mohammad T Mashal; Felix Masiye; Amanda J Mason-Jones; Kunihiro Matsushita; Richard Matzopoulos; Bongani M Mayosi; Tasara T Mazorodze; Abigail C McKay; Martin McKee; Abigail McLain; Peter A Meaney; Catalina Medina; Man Mohan Mehndiratta; Fabiola Mejia-Rodriguez; Wubegzier Mekonnen; Yohannes A Melaku; Michele Meltzer; Ziad A Memish; Walter Mendoza; George A Mensah; Atte Meretoja; Francis Apolinary Mhimbira; Renata Micha; Ted R Miller; Edward J Mills; Awoke Misganaw; Santosh Mishra; Norlinah Mohamed Ibrahim; Karzan A Mohammad; Ali H Mokdad; Glen L Mola; Lorenzo Monasta; Julio C Montañez Hernandez; Marcella Montico; Ami R Moore; Lidia Morawska; Rintaro Mori; Joanna Moschandreas; Wilkister N Moturi; Dariush Mozaffarian; Ulrich O Mueller; Mitsuru Mukaigawara; Erin C Mullany; Kinnari S Murthy; Mohsen Naghavi; Ziad Nahas; Aliya Naheed; Kovin S Naidoo; Luigi Naldi; Devina Nand; Vinay Nangia; K M Venkat Narayan; Denis Nash; Bruce Neal; Chakib Nejjari; Sudan P Neupane; Charles R Newton; Frida N Ngalesoni; Jean de Dieu Ngirabega; Grant Nguyen; Nhung T Nguyen; Mark J Nieuwenhuijsen; Muhammad I Nisar; José R Nogueira; Joan M Nolla; Sandra Nolte; Ole F Norheim; Rosana E Norman; Bo Norrving; Luke Nyakarahuka; In-Hwan Oh; Takayoshi Ohkubo; Bolajoko O Olusanya; Saad B Omer; John Nelson Opio; Ricardo Orozco; Rodolfo S Pagcatipunan; Amanda W Pain; Jeyaraj D Pandian; Carlo Irwin A Panelo; Christina Papachristou; Eun-Kee Park; Charles D Parry; Angel J Paternina Caicedo; Scott B Patten; Vinod K Paul; Boris I Pavlin; Neil Pearce; Lilia S Pedraza; Andrea Pedroza; Ljiljana Pejin Stokic; Ayfer Pekericli; David M Pereira; Rogelio Perez-Padilla; Fernando Perez-Ruiz; Norberto Perico; Samuel A L Perry; Aslam Pervaiz; Konrad Pesudovs; Carrie B Peterson; Max Petzold; Michael R Phillips; Hwee Pin Phua; Dietrich Plass; Dan Poenaru; Guilherme V Polanczyk; Suzanne Polinder; Constance D Pond; C Arden Pope; Daniel Pope; Svetlana Popova; Farshad Pourmalek; John Powles; Dorairaj Prabhakaran; Noela M Prasad; Dima M Qato; Amado D Quezada; D Alex A Quistberg; Lionel Racapé; Anwar Rafay; Kazem Rahimi; Vafa Rahimi-Movaghar; Sajjad Ur Rahman; Murugesan Raju; Ivo Rakovac; Saleem M Rana; Mayuree Rao; Homie Razavi; K Srinath Reddy; Amany H Refaat; Jürgen Rehm; Giuseppe Remuzzi; Antonio L Ribeiro; Patricia M Riccio; Lee Richardson; Anne Riederer; Margaret Robinson; Anna Roca; Alina Rodriguez; David Rojas-Rueda; Isabelle Romieu; Luca Ronfani; Robin Room; Nobhojit Roy; George M Ruhago; Lesley Rushton; Nsanzimana Sabin; Ralph L Sacco; Sukanta Saha; Ramesh Sahathevan; Mohammad Ali Sahraian; Joshua A Salomon; Deborah Salvo; Uchechukwu K Sampson; Juan R Sanabria; Luz Maria Sanchez; Tania G Sánchez-Pimienta; Lidia Sanchez-Riera; Logan Sandar; Itamar S Santos; Amir Sapkota; Maheswar Satpathy; James E Saunders; Monika Sawhney; Mete I Saylan; Peter Scarborough; Jürgen C Schmidt; Ione J C Schneider; Ben Schöttker; David C Schwebel; James G Scott; Soraya Seedat; Sadaf G Sepanlou; Berrin Serdar; Edson E Servan-Mori; Gavin Shaddick; Saeid Shahraz; Teresa Shamah Levy; Siyi Shangguan; Jun She; Sara Sheikhbahaei; Kenji Shibuya; Hwashin H Shin; Yukito Shinohara; Rahman Shiri; Kawkab Shishani; Ivy Shiue; Inga D Sigfusdottir; Donald H Silberberg; Edgar P Simard; Shireen Sindi; Abhishek Singh; Gitanjali M Singh; Jasvinder A Singh; Vegard Skirbekk; Karen Sliwa; Michael Soljak; Samir Soneji; Kjetil Søreide; Sergey Soshnikov; Luciano A Sposato; Chandrashekhar T Sreeramareddy; Nicolas J C Stapelberg; Vasiliki Stathopoulou; Nadine Steckling; Dan J Stein; Murray B Stein; Natalie Stephens; Heidi Stöckl; Kurt Straif; Konstantinos Stroumpoulis; Lela Sturua; Bruno F Sunguya; Soumya Swaminathan; Mamta Swaroop; Bryan L Sykes; Karen M Tabb; Ken Takahashi; Roberto T Talongwa; Nikhil Tandon; David Tanne; Marcel Tanner; Mohammad Tavakkoli; Braden J Te Ao; Carolina M Teixeira; Martha M Téllez Rojo; Abdullah S Terkawi; José Luis Texcalac-Sangrador; Sarah V Thackway; Blake Thomson; Andrew L Thorne-Lyman; Amanda G Thrift; George D Thurston; Taavi Tillmann; Myriam Tobollik; Marcello Tonelli; Fotis Topouzis; Jeffrey A Towbin; Hideaki Toyoshima; Jefferson Traebert; Bach X Tran; Leonardo Trasande; Matias Trillini; Ulises Trujillo; Zacharie Tsala Dimbuene; Miltiadis Tsilimbaris; Emin Murat Tuzcu; Uche S Uchendu; Kingsley N Ukwaja; Selen B Uzun; Steven van de Vijver; Rita Van Dingenen; Coen H van Gool; Jim van Os; Yuri Y Varakin; Tommi J Vasankari; Ana Maria N Vasconcelos; Monica S Vavilala; Lennert J Veerman; Gustavo Velasquez-Melendez; N Venketasubramanian; Lakshmi Vijayakumar; Salvador Villalpando; Francesco S Violante; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Gregory R Wagner; Stephen G Waller; Mitchell T Wallin; Xia Wan; Haidong Wang; JianLi Wang; Linhong Wang; Wenzhi Wang; Yanping Wang; Tati S Warouw; Charlotte H Watts; Scott Weichenthal; Elisabete Weiderpass; Robert G Weintraub; Andrea Werdecker; K Ryan Wessells; Ronny Westerman; Harvey A Whiteford; James D Wilkinson; Hywel C Williams; Thomas N Williams; Solomon M Woldeyohannes; Charles D A Wolfe; John Q Wong; Anthony D Woolf; Jonathan L Wright; Brittany Wurtz; Gelin Xu; Lijing L Yan; Gonghuan Yang; Yuichiro Yano; Pengpeng Ye; Muluken Yenesew; Gökalp K Yentür; Paul Yip; Naohiro Yonemoto; Seok-Jun Yoon; Mustafa Z Younis; Zourkaleini Younoussi; Chuanhua Yu; Maysaa E Zaki; Yong Zhao; Yingfeng Zheng; Maigeng Zhou; Jun Zhu; Shankuan Zhu; Xiaonong Zou; Joseph R Zunt; Alan D Lopez; Theo Vos; Christopher J Murray
Journal:  Lancet       Date:  2015-09-11       Impact factor: 79.321

9.  Association of hypertension and hyperglycaemia with socioeconomic contexts in resource-poor settings: the Bangladesh Demographic and Health Survey.

Authors:  Eric Harshfield; Rajiv Chowdhury; Meera N Harhay; Henry Bergquist; Michael O Harhay
Journal:  Int J Epidemiol       Date:  2015-07-06       Impact factor: 7.196

10.  Prevalence and Associated Factors of Hypertension: A Community-Based Cross-Sectional Study in Municipalities of Kathmandu, Nepal.

Authors:  Raja Ram Dhungana; Achyut Raj Pandey; Bihungum Bista; Suira Joshi; Surya Devkota
Journal:  Int J Hypertens       Date:  2016-05-12       Impact factor: 2.420

View more
  18 in total

1.  Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.

Authors:  Yan-Feng Zhou; Na Liu; Pei Wang; Jae Jeong Yang; Xing-Yue Song; Xiong-Fei Pan; Xiaomin Zhang; Meian He; Honglan Li; Yu-Tang Gao; Yong-Bing Xiang; Tangchun Wu; Danxia Yu; An Pan
Journal:  Hypertension       Date:  2020-07-27       Impact factor: 10.190

Review 2.  Prevalence of high blood pressure under 2017 ACC/AHA guidelines: a systematic review and meta-analysis.

Authors:  Peisheng Xiong; Zhixi Liu; Meijuan Xiong; Feng Xie
Journal:  J Hum Hypertens       Date:  2020-12-08       Impact factor: 3.012

3.  Determinants of hypertension among adults in Bangladesh as per the Joint National Committee 7 and 2017 American College of Cardiology/American Hypertension Association hypertension guidelines.

Authors:  Gulam Muhammed Al Kibria; Krystal Swasey; Md Zabir Hasan; Allysha Choudhury; Rajat Das Gupta; Samuel A Abariga; Atia Sharmeen; Vanessa Burrowes
Journal:  J Am Soc Hypertens       Date:  2018-10-22

4.  Hypertension in Adults With Intellectual Disability: Prevalence and Risk Factors.

Authors:  Elizabeth C Schroeder; Lindsay DuBois; Molly Sadowsky; Thessa I M Hilgenkamp
Journal:  Am J Prev Med       Date:  2020-02-12       Impact factor: 5.043

5.  Evidence for an expanded hypertension care cascade in low- and middle-income countries: a scoping review.

Authors:  Michael A Peters; Caitlin M Noonan; Krishna D Rao; Anbrasi Edward; Olakunle O Alonge
Journal:  BMC Health Serv Res       Date:  2022-06-27       Impact factor: 2.908

6.  Impact of the 2017 American College of Cardiology/American Heart Association Guidelines on Prevalence of Hypertension in Ghana.

Authors:  Samuel A Abariga; Gulam Muhammed Al Kibria; Jennifer S Albrecht
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

7.  Hypertension prevalence and control in Ulaanbaatar, Mongolia.

Authors:  Harry Potts; Uurtsaikh Baatarsuren; Maral Myanganbayar; Baigal Purevdorj; Burtu-Ujin Lkhagvadorj; Namuun Ganbat; Alimaa Dorjpalam; Delgerbat Boldbaatar; Khulan Tuvdendarjaa; Dulmaa Sampilnorov; Khatantuul Boldbaatar; Myagmartseren Dashtseren; Batbold Batsukh; Namkhaidorj Tserengombo; Tsolmon Unurjargal; Enkhtuya Palam; Roberta Bosurgi; Geoffrey So; Norm R C Campbell; Andreas Bungert; Naranbaatar Dashdorj; Naranjargal Dashdorj
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-08       Impact factor: 3.738

8.  Relationship of the Blood Pressure Categories, as Defined by the ACC/AHA 2017 Blood Pressure Guidelines, and the Risk of  Development of Cardiovascular Disease in Low-Risk Young  Adults: Insights From a Retrospective Cohort of Young Adults.

Authors:  Seolhye Kim; Yoosoo Chang; Jeonggyu Kang; Ara Cho; Juhee Cho; Yun Soo Hong; Di Zhao; Jiin Ahn; Hocheol Shin; Eliseo Guallar; Seungho Ryu; Ki-Chul Sung
Journal:  J Am Heart Assoc       Date:  2019-05-29       Impact factor: 5.501

9.  Factors associated with hypertension among adults in Nepal as per the Joint National Committee 7 and 2017 American College of Cardiology/American Heart Association hypertension guidelines: a cross-sectional analysis of the demographic and health survey 2016.

Authors:  Rajat Das Gupta; Sojib Bin Zaman; Kusum Wagle; Reese Crispen; Mohammad Rashidul Hashan; Gulam Muhammed Al Kibria
Journal:  BMJ Open       Date:  2019-08-10       Impact factor: 2.692

10.  Socioeconomic differentials in hypertension based on JNC7 and ACC/AHA 2017 guidelines mediated by body mass index: Evidence from Nepal demographic and health survey.

Authors:  Juwel Rana; Zobayer Ahmmad; Kanchan Kumar Sen; Sanjeev Bista; Rakibul M Islam
Journal:  PLoS One       Date:  2020-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.